184 top medical experts on Facioscapulohumeral muscular dystrophy 1a across 13 countries and 8 U.S. states, including 22 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants.

  1. Facioscapulohumeral muscular dystrophy 1a: Facioscapulohumeral muscular dystrophy is a disorder characterized by muscle weakness and wasting (atrophy). This condition gets its name from the areas of the body that are affected most often: muscles in the face (facio-), around the shoulder blades (scapulo-), and in the upper arms (humeral). The signs and symptoms of facioscapulohumeral muscular dystrophy usually appear in adolescence. However, the onset and severity of the condition varies widely. Facioscapulohumeral muscular dystrophy results from a deletion of genetic material from a region of DNA known as D4Z4. This region is located near one end of chromosome 4 . It is inherited in an autosomal dominant pattern.
  2. Clinical guidelines are the recommended starting point to understand initial steps and current protocols in any disease or procedure:
  3. Support Organizations

Organizations Providing General Support

  • Synonyms: FSHD1A,  FSHMD1A,  Facioscapulohumeral dystrophy with sensorineural hearing loss and tortuosity of retinal arterioles,  infantile Facioscapulohumeral muscular dystrophy,  Landouzy-dejerine muscular dystrophy,  type 1a facioscapulohumeral Muscular dystrophy


    •   

            

                        


      Computing Expert Listing ...